Sonelokimab for Hidradenitis Suppurativa
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate the effectiveness and safety of the drug sonelokimab for teens with hidradenitis suppurativa (HS), a skin condition that causes painful lumps. Participants will receive sonelokimab injections over a period to assess its effects. The trial seeks teens who have experienced moderate to severe HS for over six months and have not responded well to antibiotics. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to potentially bringing a new treatment to market.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that sonelokimab is likely to be safe for humans?
Research has shown that sonelokimab is generally well-tolerated. In one study, sonelokimab was tested for hidradenitis suppurativa, a skin condition that causes painful bumps, and demonstrated good safety results. Another study examined its long-term safety, and most participants found it manageable.
The studies also indicated that the treatment significantly improved the condition, with some participants responding better to sonelokimab than to a placebo. This suggests that while the treatment is effective, it also maintains a good safety record. However, like any treatment, side effects may occur, so participants should discuss any concerns with their healthcare provider.12345Why do researchers think this study treatment might be promising for HS?
Most treatments for hidradenitis suppurativa, like antibiotics and TNF inhibitors, aim to reduce inflammation and manage symptoms. But Sonelokimab works differently, targeting a specific protein called IL-17A that plays a critical role in inflammatory processes. Researchers are excited because this targeted approach may offer more effective relief with fewer side effects. Plus, Sonelokimab is administered subcutaneously, which could be more convenient for patients compared to some current options.
What evidence suggests that sonelokimab might be an effective treatment for hidradenitis suppurativa?
Research has shown that sonelokimab holds promise for treating hidradenitis suppurativa (HS). In recent studies, 35.4% of patients taking sonelokimab experienced a 75% reduction in symptoms, compared to only 21.6% of those not receiving the treatment. Additionally, about 1 in 4 patients achieved complete relief from inflammation after 24 weeks. These findings suggest that sonelokimab can significantly reduce the painful symptoms of HS for many people. Overall, early data indicates that this treatment is effective, offering hope to those affected by this challenging skin condition.12367
Are You a Good Fit for This Trial?
This trial is for adolescents with moderate to severe Hidradenitis Suppurativa (HS), a skin condition that causes small, painful lumps under the skin. The study aims to understand how the body processes Sonelokimab and its safety in this age group.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Induction Treatment
Participants receive sonelokimab 120mg subcutaneously as an induction regimen of 4 doses
Maintenance Treatment
Participants receive sonelokimab subcutaneously every 4 weeks as a maintenance dose starting at Week 8
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Sonelokimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
MoonLake Immunotherapeutics AG
Lead Sponsor